Search

Your search keyword '"Steven D, Pearson"' showing total 243 results

Search Constraints

Start Over You searched for: Author "Steven D, Pearson" Remove constraint Author: "Steven D, Pearson"
243 results on '"Steven D, Pearson"'

Search Results

1. Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States

2. Institute for Clinical and Economic Review – Peterson Health Technology Institute value assessment framework for digital health technologies

3. Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure

4. White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market

5. Bedside estimates of dead space using end-tidal CO2 are independently associated with mortality in ARDS

6. Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non–Muscle Invasive Bladder Cancer

8. The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics

10. The next generation of rare disease drug policy: ensuring both innovation and affordability

16. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19

18. Management of Respiratory Failure

19. The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States

24. Potential policy reforms to strengthen the accelerated approval pathway

25. The effectiveness and value of aducanumab for Alzheimer’s disease

26. The effectiveness and value of belimumab and voclosporin for lupus nephritis

27. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma

28. The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD

29. The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer

30. Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a 'Shared Savings' Approach to Cost Offsets

31. Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals

32. The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors

33. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes

34. The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder

35. Early Rehabilitation Feasibility in a COVID-19 ICU

36. The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis

37. The effectiveness and value of novel treatments for cystic fibrosis

38. ATS Core Curriculum 2020. Adult Critical Care Medicine

39. The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus

40. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease

41. The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy

42. The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy

43. Evolving targets for sedation during mechanical ventilation

44. The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression

47. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors

49. Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

50. Performing Cost-Effectiveness Analyses to Support Policy Making: Key Lessons From the Assessment of Aducanumab

Catalog

Books, media, physical & digital resources